🇺🇸 FDA
Patent

US 8663681

Oral dosage forms comprising progesterone and methods of making and using the same

granted A61KA61K31/57A61K9/1623

Quick answer

US patent 8663681 (Oral dosage forms comprising progesterone and methods of making and using the same) held by TEVA WOMEN'S HEALTH, INC. expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA WOMEN'S HEALTH, INC.
Grant date
Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/57, A61K9/1623, A61K9/1635, A61K9/1664